Insider filing · SYRE
Scott L Burrows
Chief Financial Officer
profile →
Spyre Therapeutics, Inc.
SYRE · Healthcare · 29 filings in 24 months
ticker →
Scott L Burrows sold $300K of Spyre Therapeutics (SYRE)
Executed Sep 2 2025, disclosed Sep 3 2025, 1 day later.
Value, as filed
$300K
18,428 sh × $16.26
Executed
Sep 2 2025
the trade date, as filed
Disclosed
Sep 3 2025
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
SBScott L Burrows (Chief Financial Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Spyre Therapeutics, Inc. (SYRE). The largest single filing was $2.2M of SYRE (24,632 sh across 3 lots, as filed), executed Sep 1.
The name
SYREHealthcare · Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Scott L Burrows in SYRE
SYRESALE
Spyre Therapeutics, Inc.
$2.2M24,632 sh across 3 lots
Exec Sep 1
Filed Sep 3 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. $707K
7,400 sh across 2 lots
Exec Aug 3
Filed Aug 5 · 9:32 PM ET SYRESALE Spyre Therapeutics, Inc. $658K
7,500 sh across 2 lots
Exec Jul 1
Filed Jul 2 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. $1.3M
15,000 sh across 2 lots
Exec Jun 25
Filed Jun 26 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $533K
7,500 sh across 3 lots
Exec Jun 1
Filed Jun 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $892K
12,500 sh × $71.37
Exec May 1
Filed May 1 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $305K
6,200 sh × $49.21
Exec Apr 1
Filed Apr 3 · 5:30 PM ET